Prof. Gabriel E. Gondolesi, MD, MAAC, FACS, was born in Tandil on 6/11/1968. Graduated from UNLP. Surgical Resident in La Plata. Fellow in Liver Transplantation (LT) at the Favaloro Foundation - FF (1997-1999), and in Multiorgan Transplantation at Mount Sinai Hospital in New York (1999-2001). Associate Professor in LT and Chief of Intestinal Transplantation (2001-2005). In 2006, he returned to FF; performed the first adult and pediatric intestinal transplants, the first Hepato-Pulmonary transplant, and the first LT with LD for colon cancer metastasis successfully in Argentina; the first Liver-Intestinal transplant, the first Domino + Split LT in LatAm, and the first LT with grafts from two living donors (LD) in the Americas. Health Researcher at CONICET. Author of 160 publications, director of 7 theses. Doctor Honoris Causa from the Universidad San Francisco Javier de Chuquisaca (2012). Received 20 national and international awards. Served as Chairman of the 2015 ISBTS and CO-Chairman of TTS2022, Past-President of IRTA, Senior treasurer of TTS, Member of the WHO Donation and Transplantation Working Group. Winner of the Konex Award in Surgery 2023.

Dorry Segev is Professor of Surgery and Population Health at NYU, and founding director of the NYU Center for Surgical and Transplant Applied Research. He has worked in transplantation for two decades, fulfilling important roles in UNOS/OPTN, SRTR, ASTS, AST, and TTS. In addition to serving as TTS Councilor, Dr. Segev created and chaired the TTS Global Data Harmonization committee, served on the program planning committee for many past TTS Congresses, co-chaired the TTS Masterclass Series, and recently served on the 2023 TTS Council Cape Town Strategic Planning Retreat, the 2023 TTS Meetings Advisory Committee, and the 2024 TTS Finance Committee. He was responsible for the first US HIV-to-HIV transplants, receiving official recognition from US President Barack Obama. He was also the first to demonstrate poor immunogenicity to COVID vaccines in the immunocompromised, for which he received a Letter of Commendation from Dr. Anthony Fauci. His research includes kidney exchange, desensitization, long-term donor risk, racial and geographic disparities, artificial intelligence, and post-transplant outcomes. He has published over 900 peer-reviewed articles, is ranked #1 worldwide in transplant expertise and influence by ExpertScape, and is one of select few transplant surgeons appointed to the National Academy of Medicine. He received Foreign Policy Magazine's prestigious Global Thinker Award, and was named an Innovator of the Year by TIME Magazine. He strongly prioritizes mentorship, and is the only surgeon in the US funded by an NIH/NIAID Mentoring Grant for this purpose. He most values TTS’s role in developing the next generation of transplant professionals.

Peter Stock, MD, PhD, Professor of Surgery at the University of California, San Francisco, has long served the transplant community, and remains clinically active in pancreas, liver, and kidney transplantation. He has extensive experience in the surgeon-scientist role, with NIH funding in the areas of cellular transplantation and solid organ transplantation in the HIV-infected transplant recipient. Dr. Stock has served the TTS in following capacities: TTS Education Committee (2011-1014); TTS Councilor (2017-2021), (2023-current); IPITA Councilor (2011-2015); Chair of the TTS ethics committee (2019-2023); TTS India Relations Committee; and the TTS COVID-19 Task Force (2020-current). He has served as President of the American Society of Transplant Surgeons (2014-2015) and is currently chair of the UNOS International Ad Hoc Committee.  As the US James IVth travelling surgical fellow (2000), visits to transplant programs in Australia (Sydney), South Africa (Cape Town), India (Chennai), China (Hong Kong), Korea (Seoul), and UK (Oxford) set the foundation for ongoing relationships that will facilitate moving the agenda of the TTS forward. As a potential vice president and current counselor, he will utilize his global experience and network to focus on the clinical translation of the 2024 WHO resolution directed at expanding access and facilitating the development of transplantation (solid organ and cellular) in resource constrained areas.